Your browser is no longer supported. Please, upgrade your browser.
Settings
FIXX [NASD]
Homology Medicines, Inc.
Index- P/E- EPS (ttm)-1.80 Insider Own12.61% Shs Outstand56.50M Perf Week10.25%
Market Cap463.20M Forward P/E- EPS next Y-2.40 Insider Trans-0.00% Shs Float49.89M Perf Month26.42%
Income-89.60M PEG- EPS next Q-0.60 Inst Own69.90% Short Float5.58% Perf Quarter19.15%
Sales33.00M P/S14.04 EPS this Y-13.60% Inst Trans12.59% Short Ratio5.74 Perf Half Y-8.70%
Book/sh3.97 P/B2.19 EPS next Y-33.30% ROA-36.40% Target Price- Perf Year-18.90%
Cash/sh4.01 P/C2.17 EPS next 5Y-9.40% ROE-45.30% 52W Range5.94 - 15.24 Perf YTD-22.85%
Dividend- P/FCF- EPS past 5Y- ROI-66.50% 52W High-42.85% Beta-0.42
Dividend %- Quick Ratio11.20 Sales past 5Y- Gross Margin- 52W Low46.64% ATR0.37
Employees205 Current Ratio11.20 Sales Q/Q266.70% Oper. Margin- RSI (14)72.41 Volatility4.50% 4.50%
OptionableYes Debt/Eq0.00 EPS Q/Q30.90% Profit Margin- Rel Volume0.89 Prev Close8.20
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume485.20K Price8.71
Recom1.60 SMA2014.50% SMA5024.99% SMA200-0.97% Volume433,207 Change6.22%
Mar-02-21Initiated Stifel Hold $14
Dec-14-20Resumed H.C. Wainwright Buy $30
Aug-11-20Reiterated H.C. Wainwright Buy $37 → $30
Jun-25-20Resumed BofA/Merrill Buy $30
May-13-20Initiated RBC Capital Mkts Outperform $30
Mar-16-20Upgrade Oppenheimer Perform → Outperform $32
Feb-24-20Initiated Chardan Capital Markets Buy $34
Nov-01-19Initiated Oppenheimer Perform
Sep-10-19Initiated Robert W. Baird Outperform
Apr-12-19Initiated Evercore ISI Outperform
Feb-20-19Initiated H.C. Wainwright Buy $36
Jan-07-19Initiated Canaccord Genuity Buy $37
Sep-07-18Initiated B. Riley FBR Neutral $18.50
Aug-14-21 03:27AM  
Aug-12-21 07:05PM  
04:05PM  
Aug-05-21 08:30AM  
Aug-04-21 08:30AM  
Aug-02-21 03:01PM  
Jun-19-21 05:23AM  
May-13-21 07:00AM  
May-06-21 06:15PM  
04:05PM  
May-03-21 08:00AM  
Apr-29-21 05:06PM  
Apr-28-21 08:00AM  
Apr-20-21 03:28AM  
Apr-14-21 08:30AM  
Apr-12-21 08:30AM  
Apr-07-21 12:15PM  
08:52AM  
Apr-06-21 04:19PM  
Mar-22-21 08:00AM  
Mar-11-21 07:05PM  
04:10PM  
Mar-04-21 12:30PM  
Mar-01-21 09:51AM  
07:30AM  
Feb-25-21 08:00AM  
Feb-19-21 02:30AM  
Feb-08-21 02:50PM  
Jan-06-21 08:00AM  
Dec-14-20 01:36PM  
Dec-11-20 07:05PM  
02:15PM  
Nov-25-20 10:36AM  
Nov-10-20 03:05PM  
Nov-09-20 07:00PM  
05:35PM  
04:05PM  
08:00AM  
Nov-08-20 09:56AM  
Nov-06-20 11:40AM  
Nov-05-20 09:15AM  
Nov-03-20 12:30PM  
Oct-29-20 06:50PM  
Oct-28-20 07:45PM  
Oct-27-20 06:13PM  
Oct-26-20 09:32PM  
05:37PM  
Oct-23-20 10:00PM  
02:25PM  
Oct-22-20 04:35PM  
08:30AM  
Oct-21-20 07:56PM  
12:26PM  
Oct-20-20 07:04PM  
Oct-19-20 03:35PM  
Oct-16-20 04:53PM  
Oct-15-20 01:33PM  
01:30PM  
12:00PM  
11:53AM  
11:30AM  
Oct-14-20 06:23PM  
05:28PM  
Oct-13-20 08:20PM  
04:30PM  
03:12PM  
02:55PM  
01:49PM  
10:55AM  
Oct-12-20 06:10PM  
05:00PM  
Oct-09-20 10:13PM  
04:15PM  
Oct-08-20 09:44PM  
Sep-18-20 09:00AM  
Aug-10-20 05:35PM  
04:05PM  
12:39PM  
12:38PM  
Aug-06-20 12:30PM  
Jul-27-20 11:42PM  
Jul-21-20 08:00AM  
Jul-08-20 08:49AM  
Jun-29-20 10:49AM  
Jun-27-20 02:58PM  
May-26-20 02:11PM  
May-19-20 04:08PM  
May-12-20 08:00AM  
May-10-20 09:45AM  
May-07-20 04:05PM  
Apr-29-20 08:00AM  
Apr-03-20 09:44AM  
Mar-16-20 09:00AM  
Mar-14-20 09:14AM  
Mar-12-20 05:45PM  
04:10PM  
Mar-11-20 09:22AM  
Mar-03-20 12:30PM  
Feb-20-20 09:00AM  
Feb-17-20 10:06AM  
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Timothy PSee Remarks.Sep 03Sale7.70544160Sep 08 04:10 PM
Kelly Timothy PSee Remarks.Mar 01Option Exercise4.764,00019,0526,232Mar 03 04:05 PM
Smith W BradfordCFO & TreasurerFeb 08Option Exercise0.6413,5008,64013,500Feb 09 04:22 PM
Smith W BradfordCFO & TreasurerFeb 08Sale14.2513,500192,4250Feb 09 04:22 PM
Kelly Timothy PSee RemarksFeb 02Option Exercise6.635003,316500Feb 05 06:31 AM
Kelly Timothy PSee RemarksFeb 02Sale13.005006,5000Feb 05 06:31 AM
Kelly Timothy PSee RemarksFeb 01Option Exercise4.764,00019,0524,000Feb 03 04:05 PM
Kelly Timothy PSee RemarksFeb 01Sale12.374,00049,4600Feb 03 04:05 PM
Kelly Timothy PSee RemarksJan 12Option Exercise6.635003,316500Jan 14 04:05 PM
Kelly Timothy PSee RemarksJan 12Sale13.005006,5000Jan 14 04:05 PM
Seymour AlbertChief Scientific OfficerJan 07Sale12.055,10361,469129,017Jan 08 04:05 PM
Seymour AlbertChief Scientific OfficerJan 06Sale12.069,897119,395134,120Jan 08 04:05 PM
Seymour AlbertChief Scientific OfficerJan 05Sale11.4410,000114,422144,017Jan 07 04:05 PM
Kelly Timothy PSee RemarksJan 04Option Exercise4.764,00019,0524,000Jan 06 04:05 PM
Kelly Timothy PSee RemarksJan 04Sale11.504,00045,9830Jan 06 04:05 PM
PARMAR KUSHDirectorDec 22Sale12.82500,0006,410,000181,435Dec 28 09:37 PM
5AM Ventures IV, L.P.10% OwnerDec 22Sale12.82500,0006,410,000181,435Dec 28 09:35 PM
PARMAR KUSHDirectorDec 14Sale12.25500,0006,125,915201,435Dec 16 07:25 PM
5AM Ventures IV, L.P.10% OwnerDec 14Sale12.25500,0006,125,915201,435Dec 16 07:15 PM